Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2161 AL 2175

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10.

Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial

Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):759-66. doi: 10.1212/WNL.0b013e31822affb0. Epub 2011 Aug 10.

MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study

Morelli M, Arabia G, Novellino F, Salsone M, Giofrè L, Condino F, Messina D, Quattrone A.

Neurology. 2011 Sep 13;77(11):1042-7. doi: 10.1212/WNL.0b013e31822e55d0. Epub 2011 Aug 10.

Organotypic vibrosections: novel whole sagittal brain cultures

Ullrich C, Daschil N, Humpel C.

J Neurosci Methods. 2011 Sep 30;201(1):131-41. doi: 10.1016/j.jneumeth.2011.07.021. Epub 2011 Jul 30.

Functional connectivity and integrative properties of globus pallidus neurons

Jaeger D, Kita H.

Neuroscience. 2011 Dec 15;198:44-53. doi: 10.1016/j.neuroscience.2011.07.050. Epub 2011 Jul 27.

Site of deep brain stimulation and jaw velocity in Parkinson disease

Robertson LT, St George RJ, Carlson-Kuhta P, Hogarth P, Burchiel KJ, Horak FB.

J Neurosurg. 2011 Nov;115(5):985-94. doi: 10.3171/2011.7.JNS102173. Epub 2011 Aug 12.

An update on adenosine A2A receptors as drug target in Parkinson's disease

Vallano A, Fernandez-Duenas V, Pedros C, Arnau JM, Ciruela F.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):659-69. doi: 10.2174/187152711797247803.

Drug targets from genetics: α-synuclein

Danzer KM, McLean PJ.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):712-23. doi: 10.2174/187152711797247867.

Editorial hot topic: drug targets in Parkinson's disease: where are we and where should we go?]

Cookson MR.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):650. doi: 10.2174/187152711797247830.

Is rTMS an effective therapeutic strategy that can be used to treat Parkinson's disease?

Arias-Carrion O, Machado S, Paes F, Velasques B, Teixeira S, Cardenas-Morales L, Piedade R, Ribeiro P, Nardi AE.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):693-702. doi: 10.2174/187152711797247821.

GDNF family ligands: a potential future for Parkinson's disease therapy

Mickiewicz AL, Kordower JH.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):703-11. doi: 10.2174/187152711797247876.

Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease

Cenci MA, Ohlin KE, Odin P.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):670-84. doi: 10.2174/187152711797247885.

Targeting nicotinic receptors for Parkinson's disease therapy

Quik M, Bordia T, Huang L, Perez X.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):651-8. doi: 10.2174/187152711797247849.

Kinases as targets for Parkinson's disease: from genetics to therapy

Vancraenenbroeck R, Lobbestael E, Maeyer MD, Baekelandt V, Taymans JM.

CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):724-40. doi: 10.2174/187152711797247858.

Endoscopic third ventriculotomy improves parkinsonism following a ventriculo-peritoneal shunt in a patient with non-communicating hydrocephalus secondary to idiopathic aqueduct stenosis

Hashizume A, Watanabe H, Matsuo K, Katsuno M, Tanaka F, Nagatani T, Sobue G.

J Neurol Sci. 2011 Oct 15;309(1-2):148-50. doi: 10.1016/j.jns.2011.07.025. Epub 2011 Aug 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias